Merck also publishes results before exceptional better than expected
July 30, 2010 - 11:55 pm
Merck reported a quarterly results better than expected thanks to strong demand for its treatment fighting against diabetes, arthritis or AIDS.
Excluding items, profit U.S. lab amounts to 86 cents per share while analysts polled by Thomson Reuters I / B / E / S had forecast 83 cents.
In total, net income fell to 752 million or 24 cents per share.In the second quarter of 2009, it was 1.56 billion or 74 cents a share.
Merck has taken control of his compatriot Schering-Plough in November for $ 41 billion.
For the year, Merck now expects EPS of 3.29 to 3.39 dollars per share, excluding special items, a slight adjustment from its previous forecast of 3.27 to 3.41 dollars.
In pre-market, Merck was down 2.2% to 34.29 dollars.